ST PharmLtd (A237690) Stock Overview
Provides manufacturing services for active pharmaceutical ingredient and intermediate. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A237690 from our risk checks.
A237690 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ST Pharm Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩148,000.00 |
| 52 Week High | ₩171,500.00 |
| 52 Week Low | ₩70,800.00 |
| Beta | 0.35 |
| 1 Month Change | -7.21% |
| 3 Month Change | 6.02% |
| 1 Year Change | 91.96% |
| 3 Year Change | 87.34% |
| 5 Year Change | 29.71% |
| Change since IPO | 203.28% |
Recent News & Updates
Recent updates
ST PharmLtd's (KOSDAQ:237690) Earnings Are Of Questionable Quality
Mar 27
ST Pharm Co.,Ltd. (KOSDAQ:237690) Stocks Shoot Up 39% But Its P/S Still Looks Reasonable
Feb 02ST PharmLtd (KOSDAQ:237690) Seems To Use Debt Quite Sensibly
Jan 24Is There An Opportunity With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) 22% Undervaluation?
Dec 30Earnings Tell The Story For ST Pharm Co.,Ltd. (KOSDAQ:237690) As Its Stock Soars 27%
Dec 15ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Share Price Matching Investor Opinion
Oct 29A Look At The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)
Sep 11Is ST PharmLtd (KOSDAQ:237690) A Risky Investment?
Aug 26Here's Why ST PharmLtd (KOSDAQ:237690) Has Caught The Eye Of Investors
Aug 05Shareholders Should Be Pleased With ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Price
Jun 13ST PharmLtd (KOSDAQ:237690) Takes On Some Risk With Its Use Of Debt
May 26Calculating The Intrinsic Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)
May 07ST PharmLtd's (KOSDAQ:237690) Earnings Are Built On Soft Foundations
Apr 02Getting In Cheap On ST Pharm Co.,Ltd. (KOSDAQ:237690) Might Be Difficult
Feb 11Does ST PharmLtd (KOSDAQ:237690) Have A Healthy Balance Sheet?
Jan 21Should You Be Adding ST PharmLtd (KOSDAQ:237690) To Your Watchlist Today?
Nov 22ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up
Aug 30Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?
Aug 17Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?
May 09Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem
Mar 22ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected
Mar 18Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%
Mar 16Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)
Jan 22What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?
Dec 23Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?
Nov 26
Shareholder Returns
| A237690 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 5.0% | -5.3% | 3.6% |
| 1Y | 92.0% | 35.9% | 144.9% |
Return vs Industry: A237690 exceeded the KR Pharmaceuticals industry which returned 35.9% over the past year.
Return vs Market: A237690 underperformed the KR Market which returned 144.9% over the past year.
Price Volatility
| A237690 volatility | |
|---|---|
| A237690 Average Weekly Movement | 9.5% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 9.1% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.7% |
Stable Share Price: A237690 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A237690's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 655 | Mooje Sung | www.stpharm.co.kr |
ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions.
ST Pharm Co.,Ltd. Fundamentals Summary
| A237690 fundamental statistics | |
|---|---|
| Market cap | ₩3.08t |
| Earnings (TTM) | ₩54.99b |
| Revenue (TTM) | ₩331.68b |
Is A237690 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A237690 income statement (TTM) | |
|---|---|
| Revenue | ₩331.68b |
| Cost of Revenue | ₩199.26b |
| Gross Profit | ₩132.42b |
| Other Expenses | ₩77.43b |
| Earnings | ₩54.99b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 27, 2026
| Earnings per share (EPS) | 2.64k |
| Gross Margin | 39.92% |
| Net Profit Margin | 16.58% |
| Debt/Equity Ratio | 12.9% |
How did A237690 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/24 23:35 |
| End of Day Share Price | 2026/04/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ST Pharm Co.,Ltd. is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Myung Sun Lee | DB Financial Investment Co. Ltd. |
| Haesoon Kwon | Eugene Investment & Securities Co Ltd. |